Xbrane Biopharma AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- SEK | - |
Apr. 22 | Transcript : Xbrane Biopharma AB - Special Call | |
Mar. 18 | Xbrane Biopharma AB(OM:XBRANE) dropped from S&P Global BMI Index | CI |
Sales 2024 * | 344M 31.41M | Sales 2025 * | 680M 62.18M | Capitalization | 327M 29.85M |
---|---|---|---|---|---|
Net income 2024 * | -101M -9.23M | Net income 2025 * | 104M 9.51M | EV / Sales 2024 * | 0.55 x |
Net cash position 2024 * | 138M 12.65M | Net Debt 2025 * | 116M 10.58M | EV / Sales 2025 * | 0.65 x |
P/E ratio 2024 * |
-1.58
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.11% |
Latest transcript on Xbrane Biopharma AB
Managers | Title | Age | Since |
---|---|---|---|
Martin Åmark
CEO | Chief Executive Officer | 44 | 14-12-31 |
Anette Lindqvist
DFI | Director of Finance/CFO | 63 | 21-01-10 |
Dina Jurman
CTO | Chief Tech/Sci/R&D Officer | 42 | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 14-12-31 | |
Director/Board Member | 70 | 14-12-31 | |
Director/Board Member | 53 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |